Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIHALCON trial of consolidative radiotherapy during osimertinib for EGFR-mutated non-small cell lung cancer
jRCTs041220115Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Jan 2023; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs041220115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220115.